Everyone’s seen the commercials urging patients who have taken Xarelto to contact the law firms’ numbers onscreen immediately to join a xarelto bleeding lawsuit. Well, the drug companies are actually countering the wrongful death lawsuits and complaints contending that a third party is supporting the nationwide lawsuits as a witch hunt.
In addition, Bayer and Johnson & Johnson contend that doctors have not prescribed other drugs (namely 50-year-standing and trusted blood thinner Warfarin in its place.)
The first xarelto bleeding lawsuit began in April in New Orleans. This patient experienced severe gastrointestinal bleeding within the first month of taking Xarelto. It landed him in the hospital. There’s no antidote, and doctors had to do a costly and dangerous blood transfusions. He could have bled to death.
This claimant calls out manufacturer negligence because they did not inform doctors or patients that there is no antidote to the drug; meaning its blood thinning properties cannot be reversed once it gets to work. He was fortunate to survive, because his doctors were able to counter Xarelto with a blood transfusion in time.
Hundreds of the 10,000 other Xarelto wrongful death lawsuits time was not on their side. Many of those patients died from exactly that bleeding issue.
The Pharmaceutical Companies Respond
In response, the drug companies came back swinging with responses that seem weak. They claim Xarelto is more effective than Warfarin and is safe. Warfarin has been trusted as the main blood thinner for at least 50 years. In theory should not Warfarin also cause bleeding deaths because it too is a blood thinner?
Actually, Warfarin can cause bleeding out episodes that lead to death, if it is improperly dosed. There’s no money in suing about a long-standing blood thinner, though. If patients take too much Warfarin, they can bleed to death. Though, hospitals use Warfarin all the time without much in the way of dramatic effect other than achieving blood thinning.
The patients could file malpractice lawsuits against doctors. Yet, the question begs, why are the pharmaceutical companies only citing that the doctors did not choose to prescribe something else? Judge Fallon dismissed this argument, and the lawsuits are collectively filed under MDL 2592.
The pharma companies are also counter-claiming that a third-party is funding the xarelto bleeding lawsuit in encouraging people to join the suit. FDA is still backing its approval of Xarelto, but has issued a black box warning for the drug. Black box warnings have been issued on other blood-related pharma products over the years.
The Philadelphia Xarelto mass tort seems to be edging closer to the trial stage, and as this is happening, Bayer AG and Janssen Pharmaceuticals have hinted they want to know who are third-party lawsuit funding are. There are people providing lawsuit funding against the companies. The defendants want to know who are the people funding the plaintiffs in the Xarleto lawsuits.
Janssen and Bayer filed a motion in April. The motion was requesting the court to compel discovery in regards to third-party lawsuit funding. The motion, filed with the Philadelphia Court of Common Peas, was filed at the beginning of April.
Bellwether cases in the lawsuit have been placed on a shortlist. Defendants now want to know more about third-party ligation funding. They would like to find out more details before the selection of bellwether cases for the trials.
As of now, there are around 1,200 cases on the tort docket. However, 24 cases have qualified for bellwether status. The defendants in the case feel that in order to determine which cases on the shortlist will be tried first, then they should know who is providing the lawsuit funding.
Xarelto arrived on the market as an alternative to Warfarin, which is a well-known blood-thinner that has considered being the gold-standard. Xarelto has been proven to be effective at helping prevent blood clots and stroke in older patients. The downside of Warfarin is that strict dieting is required and there are other factors that are required in order for patients to remain in a safe zone and to avoid bleeding events, as well as serious hemorrhages.
The FDA approved Xarelto as an alternative to Warfarin, and it did not require the same amount of monitoring that Warfarin required. This is one of the reasons why the drug was touted as an effective alternative to Warfarin. It was also touted as an easier and safe alternative to Warfarin.
However, the side effects associated with Xarelto have caused a lot of problems for many people and the drug was brought to the market without an agent to reverse the thinning properties of the drug. With an infusion of Vitamin K, Warfarin can be reversed, but Xarelto doesn’t respond to Vitamin K infusions. This has led to serious issues, such as bleeding complications and there have been some deaths reported.
Plaintiffs allege that the manufacturers of the drug claimed that it didn’t require the same extent of monitoring that is required with Warfarin, but given the lack of an agent to reverse the drug’s effects, it seems that Xarelto does require a lot of monitoring. Plaintiffs also claim that the manufacturers knew that the drug couldn’t be reversed in the same manner as Warfarin, and if they knew this information, then they wouldn’t have taken the drug. Some plaintiffs said they would have consented to Xarelto if they knew.
The request to find out who is funding the plaintiffs’ lawsuits is a new trend, and the defendants said the motion was filed because they need to understand the context of the selection of bellwether cases and it is in the interest of an orderly processed. The defendants also said it may help determine if the individuals or entities have a stake in the outcome of the lawsuit. In other words, part of the reason is because the defendants want to know if any lawsuit funding has something to gain.
Lawyers represented the plaintiffs countered, saying the requests were broad. They said that it reaches into the territory of attorney-client privilege. As of now, it’s not clear if the defendants’ request will be approved or denied.
From Orleans, LA comes the news that the first trial against the medication, Xarelto, will be held in early 2017. Others are due to follow. There is a huge portfolio of xarelto claims against the maker, Jannssen Pharmaceuticals Inc., and Bayer, which are still pending. The number of cases is nearly 14,000.
The plaintiffs allege that Xarelto caused blood to thin so much that it caused serious complications to patients. As there was no antidote to the blood thinner’s power, it caused serious harm. The first plaintiff to have his trial states that he was prescribed the medication for atrial fibrillation or Afib in early 2014. One month later he was in the hospital with bleeding so severe he required many blood transfusions.
He claims the makers mislead the public about the medication’s safety. They also failed to indicate the dangers of the drug to the medical community or to the US Food and Drug Administration. They only referenced certain results from clinical trials to get the pill on the market. The issues of the medication were not disclosed.
Xarelto was compared with its rival medication, Warfarin is also known generically as Coumadin. This medication requires routine blood tests and dietary restrictions of the patients who take it. Xarelto came out as being a much easier medication to take with as much safety and effectiveness as Warfarin.
There were tests done on the two and allegations were made against the readings taken of patients by Inratio. It was believed the readings showed patients in a control group taking too much Warfarin thereby casting a better light on the Xarelto. The FDA feels that any variations in the readings done by Inratio were too slight to skew the results for Xarelto. Originally, Xarelto was approved for DVT or deep vein thrombosis.
Eventually, Xarelto was introduced to the market to be a better, easier way of managing Warfarin patients. It seemed to be too ineffective at reducing the risks of DVT or stroke from atrial fibrillation. It helped manage the levels of Warfarin used. Too much of the Warfarin itself risked hemorrhages, and bleeding.
In their xarelto claims, plaintiffs made note of the lack of an antidote available to combat the excess Xarelto bleeding. With Warfarin, patients are taken care of with a vitamin K infusion. The treatment does not work on Xarelto, leaving it to be a risky medication. Plaintiffs further claim that the makers of Xarelto were irresponsible for claiming that Xarelto required no monitoring. Because it did not have a reversing agent, the opposite became true.
Xarelto came on the market with big expectations. In the first year on the market, it brought in close to $600 million. By the end of 2013, it yielded $2 billion. The future of the drug remains to be seen as these xarelto claims lawsuits come to trial.
What makes Xarelto different than the other blood thinner medication is that it is actually a Xa inhibitor, meaning that it works to think out the blood by blocking thrombin. This is the chemical found in the blood that leads to a blood clot. Being able to block thrombin, Xarelto works to break down and then prevent any blood clot that can be a problem if you have gone through either knee replacement or hip surgery, are going through deep vein thrombosis or have been diagnosed as having atrial fibrillation.
The major side effect linked to Xarelto use is internal bleeding that is uncontrollable. Internal bleeding can be a lot more dangerous than external bleeds, as it is more difficult to identify. Since Xarelto will keep the blood from clotting, internal bleeding events can result in the need for hospitalization right away, or even death.
Along with severe internal bleeding, one serious risk that has been linked to the use of Xarelto is that it can lead to blood clotting if the person stops taking the drug before they are supposed to. This is something reported as happening whenever a patient is transitioning from Xarelto because there is no reversal agent, back to the drug Warfarin, which happens to have a reversal agent in it.
Back in 2013, the FDA put out a report that was focused on adverse medical events that are linked to the use of Xarelto. The report noted that about 2,100 of the people surveyed had reported adverse events concerning Xarelto. Out of that, 1,821 of the people cited Xarelto as being the main cause of the event.
The major four side effects to be reported in the study were:
– Deep Vein Thrombosis
– Pulmonary Embolism
– Gastrointestinal Bleeds
Some of the other adverse events that were included are cerebrovascular incidents, thrombosis, edema, dyspnea, and hematoma and hemoglobin deficiency. With 891 of the cases that were reported, hospitalization was necessary. Unfortunately, 183 of the cases resulted in the death of the patient.
A pulmonary embolism is something that happens when the blood flowing to the lungs gets blocked due to a blood clot. This is most commonly caused by a deep vein thrombosis, which is where a blood clot gets formed down in the veins of the legs or arms, then travels into the lungs where it forms a blockage. The symptoms of pulmonary embolism include severe chest pain, coughing up blood, and shortness of breath. The symptoms might only occur after serious damage is already done. A pulmonary embolism is difficult to diagnose, often leading to death.
This is internal bleeding in the abdominal area, which can be very serious. The abdominal region holds a lot of vital organs. In the event that there is an internal bleed, the blood can pool around such organs and then cut them off from the supply of blood that is freshly oxygenated. Whenever organs are cut off from oxygen for long, they will start to die. The signs of a gastrointestinal bleed can include coughing up blood or vomiting it up, resembling coffee grounds.
Internal bleeding in the brain has been always very dangerous. This can result in suffocation of the brain cells as they starve for oxygen. If they get cut off from oxygen for far too long, they can begin to die, leading to effects that are similar to a stroke. The signs that there is a brain bleed can include numbness in the arms, legs, or face, speech that is slurred, difficulty when moving or walking, harsh headaches, lack of coordination and impaired vision.
Many critics say that Xarelto is also far more dangerous than other available blood thinner medication because there is nothing that can be used as a reversal agent. If any patient that is taking Xarelto goes through internal bleeding, you do not have a drug that will counteract it to stop the bleeding.
The makers of the Xarelto drug have filed a lawsuit for patent infringement cases. Janssen Pharmaceuticals and Bayer A.G. have filed a lawsuit against the company Brecenridge Pharmaceutical, alleging that the company has tried to infringe on the Xarelto patent. Bayer is the maker of the anticoagulant in most countries; also Janssen makes it in the U.S.
Breckenridge has filed an Abbreviated New Drug Application with the FDA, which is for a generic version of the anticoagulant. Both Bayer and Janssen believe that as soon as the application is approved, Breckenridge will release their generic version of the drug. The existing patent for Xarelto, however, will not expire until the end of the year 2020.
The accusations of patent infringement cases were based on reasons, since Boehringer Ingelheim, the makers of Pradaxa, sued Brekenridge when they filed an ANDA for a generic version of Pradaxa two years ago. There are concerns that the company is too eager to enter into the anticoagulant market, and that it is throwing patent rights out of the window because of its enthusiasm.
Xarelto and Pradaxa are both big moneymakers, but there are a lot of problems with the drugs. There are lawsuits plaguing both of the medications, and concerns that Pradaxa could have some serious side-effects. Patients who experience uncontrolled bleeding, however, say that Boehringer Ingelheim did not give them sufficient warning of the risks. The company was ordered to pay out $650 million as settlements for lawsuits because of these side effects.
Xarelto is the subject of similar patent infringement cases, with Bayer and Janssen likely facing significant financial penalties because of the 6,000 lawsuits against it – which may be worse because there is no antidote, and the bleeding events can be life-threatening.
The generic version of the drug could escape some of the legal liabilities, since the makers of generics are not required to update their warnings when brand-name drugs change their warnings. They have the choice about whether or not they need to update their packaging to reflect changes.
The generic makers have limited liability because of the restrictions on them. For consumers, this means that they do not have so many rights to hold the generic makers responsible for their drugs. Janssen and Bayer, however, are not eager to hand over the rights to the drugs.
The FDA reports that there were more than 10,600 reports relating to adverse events after taking Xarelto in 2015, and that included 1,121 deaths and 4,508 injuries severe enough to require emergency treatment or hospitalisation. Xarelto is one of the poorest ranked drugs in terms of requiring hospitalization.
Xarelto is used in a lot of different scenarios, and the number of patent infringement cases is growing and growing. There will be a trial in March 2017, and it is expected that by then there could be more than 10,000 outstanding Xarelto lawsuits. Plaintiffs say that the makers misrepresented the drug. The initial approval was controversial. The manufacturers will, naturally, want to avoid a scenario of a third party getting approval for a less-risky generic version.
A Texas woman has filed a lawsuit in the federal court of the Eastern District of New York against the makers of Xarelto, a new class of blood thinner. In it, she alleges that she sustained serious injuries, signs of internal bleeding due to the company’s failure to warn her about the potential risks of using the drug and that the company failed to conduct safety testing that was sufficient before placing the blood thinner on the market. Her lawsuit is similar to many others filed against Janssen and Bayer AG. The case is listed under the federal court docket number 1:14-CV-04524 and is available in its entirety to read below.
December 7, 2015 – BloodThinnerHelp.com reports that a Texas woman has filed a lawsuit in the Eastern District of New York alleging that Janssen Pharmaceuticals and Bayer AG, the manufacturers of Xarelto, failed to provide sufficient warnings to consumers about the potential risk of the signs of internal bleeding with this blood thinner. In federal court, the latest complaint was filed under 1:14-CV-04524.
The lawsuit contains details about how the drug was prescribed to treat a condition known as atrial fibrillation. This condition can cause strokes due to blood clots. As a preventative measure, cases of this type are commonly treated with blood thinners. However, just five months after taking the blood thinner, she experienced an internal bleed that was life threatening. While the complaint does not specify much of the details of the injury, it does state that specialized care will be required due to long tern health effects that occurred as a consequence of the bleed.
After the U.S. Food and Drug Administration approved Xarelto in 2011, it was released to the market for prescription. Initially, the new drug was regarded as an option that was revolutionary, because it did not require a special diet, adjustments by physicians, or regular monitoring. However, once consumers realized that there was no antidote, this early excitement was short lived. Currently, it is seen by many to be the market’s most dangerous blood thinner.
Because there is no antidote, if a patient taking Xarelto begins to show the signs of internal bleeding after an injury, there is no way to get the blood to clot by countering the effects of the drug. In order to keep the patient alive when this happens, blood transfusions and other extreme measures to save their life must be used. In addition, operations are sometimes necessary when pools of blood develop in the spine or brain in order to relieve the built up pressure in the body by draining the blood.
Vitamin K provides an antidote for traditional blood thinners. Because of this, the effects of the traditional blood thinner are counteracted and blood clots can form when an injury occurs. It is the difference between living and dying in these cases.
Federally, there have been about 2,000 cases filed against Xarelto for bleeding that cannot be controlled. In the Eastern District of Louisiana, the Honorable Judge Eldon Fallon is overseeing the consolidation of these cases in Multidistrict litigation number 2To 592. Attorney Joseph Osborne is working to make sure that everyone has the opportunity to evaluate their legal rights if they were affected by Xarelto as these cases are prepared for trial. There may be a significant compensation for individuals who suffered adverse health effects and any signs of internal bleeding due to using Xarelto. To those involved, free legal consultations are available from attorney Osborne.
Please contact our attorney today for additional information or to ask questions about the Xarelto bleeding lawsuits.
Xarelo is a new Novel Oral Anticoagulant category (NOAC) blood-thinner medication manufactured by Johnson & Johnson and Bayer AG. It is used for treating several different conditions, including deep vein thrombosis, pulmonary embolism and atrial fibrillation. However, Xarelto is considered to be a high-risk medication and ruled responsible for serious injuries like liver damage symptoms and the deaths of several patients. Hundreds of lawsuits have been filed against the manufacturers of the drug as a result of so many individuals suffering uncontrollable internal bleeding to the point that even after being hospitalized doctors still had no way of stopping it. Unlike other similar drugs like Warfarin, there is no known antidote for reversing the effects of Xarelto, so once life-threatening bleeding takes place; the patient is at risk of death or severe injuries.
However, there are also several other potentially very serious or fatal side effects for Xarelto that are still under post-marketing investigation currently since the drug was introduced in 2008 to the worldwide market. Risk of liver damage is one of the more alarming adverse reactions that is associated with the drug Xarelto. Liver damage symptoms caused by Xarelto have been investigated for being a potential risk for individuals taking Xarelto medication. There have also been several Xarelto-induced liver injury cases that have been reported. These include several cases of acute liver failure. The results from three big international pharmacovigilance databases were recently analyzed. The analysis revealed that Xarelto was suspected to be a cause in a large number of hepatic adverse cases.
In addition to gastrointestinal bleeding and internal hemorrhage, liver damage symptoms are the most reported Xarelto side effect. It can be discovered in blood tests by elevated enzymes AST and ALT. The 4 Record study results showed that of the 6,183 patients that were treated with rivaroxaban, 2.33% had increased liver enzyme (transaminase) levels that were over 3 times higher than ULN (upper limit of normal). There were two other cases where patient showed liver damage symptoms after being treated with Xarelto which were published recently in the Journal of American Medical Association, which further confirms this drug’s alarming potential hepatotoxicity.
Another thing that should be noted is that more than two-thirds of the drug, which is administered orally, is eliminated via urine or bile following hepatic metabolism. If liver function has been comprised, the blood levels of the drug may potentially increase due to the liver being unable to eliminate a sufficient quantity of Xarelto out of the body. However, this medication’s main selling points were the fact that blood monitoring was not required and its purported safety. These points were advertised widely over the internet and television.
Without any blood monitoring, it results in patient not being aware if the effects from the drug have increased to the level of growing potentially dangerous due to an increased risk for bleeding accidents. Therefore, this requires that an appropriate adjustment to the dosage be made.
Since being treated with Xarelto can potentially be associated with symptomatic and severe liver damage symptoms and consequently bleeding risk, the physician and patient both need to be fully informed about this potentially significant danger. The drug label should include a warning about the potential symptomatic liver damage; otherwise patients who suffer liver injury as a Xarelto side effect have the right to file a lawsuit in reference to misleading information being provided by the manufacturers.
Xarleto lawsuit is one of the latest class action cases that are likely to be filed against a pharmaceutical company. It looks like pharmaceutical companies are not anywhere close to carefully checking their products before they roll them over to you. Once again, there is a new class action lawsuit in town. The tendency for the pharmaceutical companies is to focus on profits alone while ignoring the welfare of the end user has come to the fore. You could be a victim so know the things beforehand about the join class action lawsuits of Xarelto.
Xarleto is a blood thinning agent and is commonly prescribed for patients with atrial fibrillation; also referred to, commonly, as irregular heart beat condition. The drug, technically referred to as an anti coagulant is also used to prevent Deep Vein Thrombosis often denoted as DVT. Knee and hip replacement surgeons also recommend the drug to manage blood clots associated with the operation.
Xarleto is manufactured by the giant German pharmaceutical company; Bayer. In the United States, the drug is marketed by Johnson and Johnson. According to the figures released by the manufacturer, about 7 million people have used xarleto. What the legal fraternity has a keen eye on is the process of the introduction of the drug in the United States and the subsequent fast approval for its use. The speed at which the procedure led to approval raises eyebrows as has happened in the past. It seems as if the need to make more money clouded the proponents of the drug, including the FDA, to avail the drug to the public before it was sufficiently tested and found safe for use by the innocent public. You must join class action lawsuits of xarelto lawyers with the good intent of stopping this heinous trend of pharmaceutical companies putting financial gain before safety. If we don’t act in solidarity, we shall remain victims.
The main concern here is that xarleto has been seen to work well, I mean rather too well. It is true that xarleto effectively succeeds in thinning blood and consequently prevents clotting. Tests show that xarleto exceeds the limit because in the end your blood is thinned beyond safety. So, you must be wondering what the hullaballoo is about! Well, xarleto solves one problem and creates another one. The concern is that the problem created by xarleto could be more dangerous that the problem it tries to solve. Since xarleto makes your blood too thin, it then means that you stand a chance of bleeding profusely. If you are not anywhere near a medical facility, it means your life is at potential risk; you could die of bleeding. Your blood has been deprived of its natural clotting mechanism and will ooze out like a jet in greater volume because it is thinner than normal; thanks to xarleto.
Although there has been a need to develop drugs to mitigate patient conditions, including a need for blood thinning drugs, it is important that enough research is invested in a drug before it is applied in treatment. There are similar drugs that are on the market but have not drawn this negative publicity. One such example is Warfarin. The drug has been around for decades. Although, like many other drugs, Warfarin has its side effects, there was enough research, actually 60 years research, on it before it was released to the public. Xarleto on the other hand has an extremely short history. It was literally rushed to the consumer market. Furthermore, apart from the risk it clearly poses to life, it does not have its antidote pair that can slow or stop bleeding.
The big question that begs is; would anyone willingly accept to use a drug that poses a risk of
• Heart failure?
• Bleeding to death?
• Organ failure?
• Pulmonary embolism?
• Brain haemorrhage?
• Gastro intestinal bleeding?
Furthermore, would you knowingly use xarleto if you were told it has no antidote to reverse profuse bleeding?
If you have taken xarleto, or anyone in your family, friends accomplices; basically, anyone you know, you need to call your lawyer or contact our attorney so that you can begin a journey to join class action lawsuits of xarelto demanding for justice. Did you know that despite the risk the drug poses, you spend $3000 every year as compared to only $300 that other blood thinners cost? You need to join the Xarleto lawsuit.
Xarelto is a blood thinning medication that is often prescribed since it was believed to be an efficient way to treat and prevent blood clots. Xarelto is also known as Rivaroxaban and comes in 10, 15 or 20 milligrams tablets. If you are prescribed Xarelto or a relative took this medication, you should be able to obtain compensation through the class action settlements since this medication was found to lead to serious health complications.
Xarelto was typically prescribed to patients who had a high risk of forming blood clots due to irregular heartbeat, a condition known as atrial fibrillation. A lot of patients who underwent hip or knee replacement surgery were prescribed this medication to prevent blood clots from forming in the hip or knee area as a result of the surgery. Xarelto was also prescribed to treat conditions such as pulmonary embolism.
This medication works by changing the way blood coagulates. This is a good way to prevent blood clots from appearing for patients who are at risk for this health issue but taking Xarelto can lead to some serious complications since this medication can cause uncontrolled bleeding.
There are some serious side effects associated with taking Xarelto. These side effects include frequent nose bleeds, swelling, fatigue, heavy and prolonged menstrual flows, heavy bleeding when a cut occurs, bleeding of the gums, bruising, difficulty swallowing and finding blood in one’s vomit, urine or stools. Severe allergic reactions can also occur, which are typically characterized by swelling, chest tightness and a rash.
Xarelto is dangerous because it prevents blood from coagulating. This means a patient can lose enough blood to be in a life-threatening condition if an injury occurs near an organ. Because the blood cannot coagulate, pools of blood can accumulate inside of the patient’s system and lead to other complications, including liver damage. And since blood cannot coagulate, severe bleeding can lead to blood flow being completely cut from an organ. An important organ like the brain, the heart or the lungs can lose some of its ability to properly function if blood flow is cut for too long.
More importantly, this uncontrollable bleeding can result in death if the patient does not have access to an emergency room. This is why taking Xarelto is dangerous and a class action lawsuit has been filed so that patients who took the medication or people who lost a loved one due to the dangerous side effects of this drug can receive class action settlements.
A class action lawsuit is filed when a large number of individual lawsuits against the same entity exist and have been filed for the same reason. Class action lawsuits are usually filed in situations where a large number of people qualify for class action settlements but processing individual lawsuits would be time-consuming and expensive. There are more than 1,600 different lawsuits filed against the company that distributed Xarelto, and these lawsuits have been consolidated into one large class action lawsuit in Louisiana. There is also another class action lawsuit filed against this company in Canada.
You can take part in this class action lawsuit if you were prescribed this drug or if a loved one took it.
Joining the patients and families of patients who took this medication in the class action settlements means you will receive compensation if the Louisiana court rules that the drug company behind Xarelto failed to properly warn patients against the risks associated with taking this blood thinner. And given the high number of individuals lawsuits that were filed and the terrifying implications of the side effects that resulted from taking this drug, it seems very likely that plaintiffs would be granted compensation once all the evidence is reviews by the court.
Taking part in a class action lawsuit means you no longer have the right to file an individual lawsuit for the same complaint. However, you will not have to pay any attorney fees and will not have to go through the entire filing process since the lawsuit has already been filed. You should definitely consider taking part in the class action settlements if you took the medication, especially if you suffered from any of the side effects or lost a loved one.
After the latest multi-billion dollar Pradaxa litigation settlement, sufferers who experienced bleeding injuries while using the anticoagulant Xarelto may question whether they have a legitimate claim. There are more than 300 xarelto litigations
being placed in multidistrict lawsuit and much more Xarelto unwanted side effects legal cases being filed, litigants might be pardoned for thinking if xarelto litigation may ultimately match Pradaxa lawsuit. You will find resemblances: both medicines were associated with similar unwanted side effects and face similar failure-to-warn accusations. But while Pradaxa lawsuit was largely moved in 2014, xarelto litigation is now on-going.
Both Xarelto and Pradaxa are the latest generation anticoagulants, promoted to be top-quality options to warfarin. Warfarin (known through the brand of Coumadin) is still available on the market for many years to avoid thrombus and strokes, but requires blood monitoring to make sure patients remain in the therapeutic range. These latest anticoagulants are promoted as not needing blood supervising.
The problem is, however, the lack of a remedy associated with these modern anticoagulants. Anticoagulants prevent bloodstream from clots and great in stopping thrombus and strokes, but harmful for other bleeding issues. Inability of the blood to clot causes it to be harder to prevent bleeding, which means patients taking anticoagulants face a danger of severe bleeding problems. Warfarin comes with an antidote by means of vitamin k supplement. These latest anticoagulants don’t have a broadly recognized antidote, which means once patients using the drugs start bleeding, they can be vulnerable to severe health issues.
Xarelto litigation filed against Bayer and Janssen Pharmaceutical drugs claims the companies fully understood or must have been aware of the chance of serious bleeding occasions, but didn’t correctly alert patients that there is no recognized antidote to Xarelto.
Boehringer Ingelheim, the manufacturer of Pradaxa, encountered around 9,000 legal cases alleging patients were hurt or died consequently of severe bleeding periods from the drug. On May 2014, Boehringer Ingelheim decided to settle nearly 4,000 claims in condition and federal courts for approximately $650 million.
Today another oral blood thinner, Xarelto (rivaroxaban), has also been associated with serious unwanted effects. Numerous legal cases happen to be filed, declaring injuries associated with the pill including critical internal bleeding. While Xarelto isn’t just like Pradaxa, research conducted recently came to the conclusion, patients supplied with both NOACs come with an elevated chance of intestinal bleeding in comparison to patients supplied with warfarin.
Meanwhile, patients and medical researchers should cautiously consider the potential risks and compensation of Xarelto litigation by taking such new anticoagulants.